Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lawlor, D. A.
Right arrow Articles by Kreiger, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lawlor, D. A.
Right arrow Articles by Kreiger, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Vol. 152, No. 11 : 1104-1016
Copyright © 2000 by The Johns Hopkins University School of Hygiene and Public Health

LETTERS TO THE EDITOR

RE: "ANTIDEPRESSANT MEDICATION USE AND BREAST CANCER RISK"

Debbie A. Lawlor

Department of Social Medicine University of Bristol Bristol, United Kingdom

The issue of a possible association between antidepressant medication and increased risk of breast cancer is important. In the developed world, breast cancer is very common, and large numbers of women are given prescriptions for and take antidepressants. The need for quality research in this area is therefore paramount. I am concerned about the conclusions reached in the paper by Cotterchio et al. (1Go). From their results, they draw three main conclusions: 1) that there is no association between "ever" use of antidepressant medication and increased breast cancer risk; 2) that the use of tricyclic antidepressants for 2 years or more is associated with a twofold increase in risk; and 3) that ever use of the specific selective serotonine reuptake inhibitor (SSRI), paroxetine, is associated with a sevenfold increase in risk.

The first of these conclusions seems justified on the basis of the results and the a priori hypothesis. . . . [Full Text of this Article]

REFERENCES

Katherine L. Beebe, Rocco Zaninelli and Bruce Trock

SmithKline Beecham Pharmaceuticals Research and Development, North America Collegeville, PA 19426–0989
Lombardi Cancer Center Georgetown University Medical Center Washington, DC 20007

Michelle Cotterchio and Nancy Kreiger

Research Unit, Division of Preventive Oncology, Cancer Care Ontario Toronto, Ontario, M5G 2L7 Canada


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
D. A. Lawlor, K. L. Beebe, R. Zaninelli, B. Trock, M. Cotterchio, and N. Kreiger
RE: "ANTIDEPRESSANT MEDICATION USE AND BREAST CANCER RISK"
Am. J. Epidemiol., December 1, 2000; 152(11): 1104 - 1016.
[Full Text] [PDF]